| Market Cap | $2.25B-26.4% |
| Revenue (ttm) | $100.00M |
| Net Income | -$453.00M |
| EPS | -$3.60 |
| Shares Out | 143.99M |
| PE Ratio | n/a |
| Forward PE | -5.05 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,671,434 |
| Open | $15.66 |
| Previous Close | $15.78 |
| Day's Range | $15.56 - $16.66 |
| 52-Week Range | $15.56 - $31.73 |
| Beta | 1.09 |
| Analysts | Strong Buy |
| Price Target | $40.92(+161.95%) |
| Earnings Date | Nov 4, 2026 |
About RCUS
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
4 firms rating RCUS in the last 3 months, one vote each. Issuer-paid research is not counted.
$RCUS stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in RCUS holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by RCUS's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
RCUS Estimated quarterly lobbying spending
Source: U.S. Senate LDA
RCUS Revenue by Segment
| License and development services | $8.00M | 80.00% |
| R&D services | $1.00M | 10.00% |
| Other | $1.00M | 10.00% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New RCUS patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to RCUS from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from RCUS’s recent data — informational, not investment advice
What’s Behind the Score
News check: BofA price target cut and fund dumping outweigh conference participation; mixed signals on stock momentum and analyst positioning.
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| CNCR | Loncar Cancer Immunotherapy ETF | 3.32% |
| IDNA | iShares Genomics Immunology and Healthcare ETF | 1.38% |
| PSCH | Invesco S&P SmallCap Health Care ETF | 1.04% |
| CANC | Tema Oncology ETF | 0.76% |
| XSMO | Invesco S&P SmallCap Momentum ETF | 0.59% |
| BBC | Virtus Biotech Clinical Trials ETF | 0.58% |
| TDNA | T. Rowe Price Biotech ETF | 0.42% |
| XBI | State Street SPDR S&P Biotech ETF | 0.37% |
| DWAS | Invesco Dorsey Wright SmallCap Momentum ETF | 0.28% |
| VIOG | Vanguard S&P Small-Cap 600 Growth ETF | 0.18% |
| IJT | iShares S&P Small-Cap 600 Growth ETF | 0.15% |
| SLYG | State Street SPDR S&P 600 Small Cap Growth ETF | 0.15% |
Weight is the stock’s share of each fund’s holdings.
